CG Oncology: director Leonard E Post sold 1,000 shares

What happened

• The filing shows director Leonard E Post sold 1,000 shares in two open-market transactions and exercised/converted derivatives on Oct 15, 2026. Sales: 500 shares at $61.65 for $30,825 and 500 shares at $62.48 for $31,240 (total sales $62,065). Exercises/conversions: acquired 1,000 shares at $0.60 for $600 and a derivative disposition of 1,000 shares at $0.00.

Key details

• Transaction dates: Oct 15, 2026.
• Sales prices reported: weighted averages $61.65 (500 shares) and $62.48 (500 shares); footnotes report price ranges of $61.16–$62.06 and $62.27–$62.60 for the respective sales and say the reporting person will provide per-price details on request.
• Exercise details: one exercise acquired 1,000 shares at $0.60 (paid $600); one derivative disposition of 1,000 shares at $0.00. Footnote notes the awards/options were fully vested.
• Plan note: the sales were made under a Rule 10b5-1 trading plan adopted Mar 5, 2026.
• Filing date and report period: filed Oct 19, 2026; period of report Oct 15, 2026.
• Shares owned after the transaction: not specified in the provided filing excerpt.

Why it may matter

• The filing shows option/derivative exercises and open-market sales occurred on the same date; one exercise involved a cash payment of $600 and there is a separate derivative disposition reported at $0.00. A filing does not show why the insider traded or why the company acted.